Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACE2 1-618-DDC-ABD
- Development stage
- Preclinical
- Lead developer
- Northwestern University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intranasal, Intperitoneal
01
Overview
ACE2 1-618-DDC-ABD (also known as AGT002) is a bioengineered soluble human angiotensin-converting enzyme 2 (ACE2) variant developed by Northwestern University and licensed to Angiotensin Therapeutics (AngioTx). It consists of a shortened 618-amino-acid truncate of human ACE2 fused to a 5 kDa albumin-binding domain (ABD) to extend its in vivo half-life, and linked via a dimerization motif hinge-like 4-cysteine dodecapeptide (DDC) to enhance its binding affinity to the SARS-CoV-2 spike protein. ACE2 1-618-DDC-ABD acts as a decoy receptor to intercept SARS-CoV-2 and prevent viral entry into host cells, while also providing enzymatic activity to degrade excess angiotensin II and des-Arg9 bradykinin, thereby mitigating inflammation and tissue injury. It has been investigated in preclinical models for the prevention and treatment of COVID-19 and associated acute kidney injury (AKI).
- Other names
- ACE2 1-618-DDC-ABDACE-2 1-618-DDC-ABDACE 2 1-618-DDC-ABDACE2 618-DDC-ABDACE-2 618-DDC-ABDACE 2 618-DDC-ABDACE2-1-618-DDC-ABDACE-2-1-618-DDC-ABDACE 2-1-618-DDC-ABDsoluble ACE2 1-618-DDC-ABD
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ACE2 1-618-DDC-ABD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACE2 1-618-DDC-ABD.